Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Treatment of refractory autoimmune diseases with autologous stem cell transplantation: focus on juvenile idiopathic arthritis

Bone Marrow Transplantation volume 35, pages S27–S29 (2005)Cite this article

Summary:

Autologous stem cell transplantation (ASCT) can be performed in a variety of refractory autoimmune diseases. A retrospective multicenter analysis is presented to evaluate safety and efficacy of ASCT for refractory juvenile idiopathic arthritis. In all, 18 of the 34 patients (53%) with a follow-up of 12 to 60 months achieved a drug-free complete remission. There were three cases (9%) of transplant-related mortality and two cases of disease-related mortality (6%). Infectious complications were seen frequently. We propose adjustments in future protocols to reduce this mortality in this high-risk patient group.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. van Bekkum DW . Stem cell transplantation for autoimmune disorders. Preclinical experiments. Best Pract Res Clin Haematol 2004; 17: 201–222.

    Article  CAS  PubMed  Google Scholar 

  2. Marmont AM . Stem cell transplantation for autoimmune disorders. Coincidental autoimmune disease in patients transplanted for conventional indications. Best Pract Res Clin Haematol 2004; 17: 223–232.

    Article  PubMed  Google Scholar 

  3. Wallace CA, Sherry DD . Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40: 1852–1855.

    Article  CAS  PubMed  Google Scholar 

  4. Lovell DJ, Giannini EH, Reiff A et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342: 763–769.

    Article  CAS  PubMed  Google Scholar 

  5. Yokota S . Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol 2003; 15: 581–586.

    Article  CAS  PubMed  Google Scholar 

  6. Quartier P, Taupin P, Bourdeaut F et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48: 1093–1101.

    Article  CAS  PubMed  Google Scholar 

  7. Petty RE . Prognosis in children with rheumatic diseases: justification for consideration of new therapies. Rheumatology (Oxford) 1999; 38: 739–742.

    Article  CAS  Google Scholar 

  8. Spiegel LR, Schneider R, Lang BA et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 2000; 43: 2402–2409.

    Article  CAS  PubMed  Google Scholar 

  9. Giannini EH, Ruperto N, Ravelli A et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202–1209.

    Article  CAS  PubMed  Google Scholar 

  10. Ruperto N, Ravelli A, Falcini F et al. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Italian Pediatric Rheumatology Study Group. Ann Rheum Dis 1998; 57: 38–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. De Kleer IM, Brinkman DM, Ferster A et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical efficacy mortality and transplant related morbidity. Ann Rheum Dis 2004; 63: 1318–1326.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Wulffraat NM, Brinkman D, Ferster A et al. Long-term follow-up of autologous stem cell transplantation for refractory juvenile idiopathic arthritis. Bone Marrow Transplant 2003; 32 (Suppl. 1): S61–S64.

    Article  CAS  PubMed  Google Scholar 

  13. Ramanan AV, Schneider R . Macrophage activation syndrome – what's in a name!. J Rheumatol 2003; 30: 2513–2516.

    PubMed  Google Scholar 

  14. Ravelli A, De Benedetti F, Viola S, Martini A . Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 1996; 128: 275–278.

    Article  CAS  PubMed  Google Scholar 

  15. Stephan JL, Kone-Paut I, Galambrun C et al. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford) 2001; 40: 1285–1292.

    Article  CAS  Google Scholar 

  16. Silverman ED, Miller III JJ, Bernstein B, Shafai T . Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. J Pediatr 1983; 103: 872–876.

    Article  CAS  PubMed  Google Scholar 

  17. Hertzberger-ten Cate R, Cats A . Toxicity of sulfasalazine in systemic juvenile chronic arthritis. Clin Exp Rheumatol 1991; 9: 85–88.

    CAS  PubMed  Google Scholar 

  18. Prahalad S, Bove KE, Dickens D et al. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 2001; 28: 2120–2124.

    CAS  PubMed  Google Scholar 

  19. Ravelli A, Caria MC, Buratti S et al. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2001; 28: 865–867.

    CAS  PubMed  Google Scholar 

  20. Grom AA, Villanueva J, Lee S et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003; 142: 292–296.

    Article  CAS  PubMed  Google Scholar 

  21. Wulffraat NM, Rijkers GT, Elst EF et al. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem cell transplantation. Rheumatology (Oxford) 2003; 42: 375–379.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Section Immunology, University Medical Center Utrecht, Utrecht, The Netherlands

    N M Wulffraat & B Vastert

  2. Department of Rheumatology, Felix Platter Spital, University of Basel, Basel, Switzerland

    A Tyndall

Authors
  1. N M Wulffraat
    View author publications

    Search author on:PubMed Google Scholar

  2. B Vastert
    View author publications

    Search author on:PubMed Google Scholar

  3. A Tyndall
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to N M Wulffraat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wulffraat, N., Vastert, B. & Tyndall, A. Treatment of refractory autoimmune diseases with autologous stem cell transplantation: focus on juvenile idiopathic arthritis. Bone Marrow Transplant 35 (Suppl 1), S27–S29 (2005). https://doi.org/10.1038/sj.bmt.1704840

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704840

Keywords

This article is cited by

Search

Advanced search

Quick links